PedAM
Pediatric Disease Annotations & Medicines
| Disease | ovarian cancer |
| Phenotype | C0021843|bowel obstruction |
| Sentences | 5 |
| PubMedID- 24575015 | A long-term treatment with lanreotide, as reported herein, is further supported by the results of a study in which 3 patients with malignant bowel obstruction due to ovarian cancer received a monthly-administered long-acting depot form of octreotide (sandostatin lar® depot) for a period of over 9 months, with no significant toxicities reported [11]. |
| PubMedID- 20614464 | Objectives: to compare the effectiveness and safety of palliative surgery (surgery performed to control the cancer, reduce symptoms and improve quality of life for those whose cancer is not able to be entirely removed) and medical management for bowel obstruction in women with ovarian cancer. |
| PubMedID- 24189059 | Objective: salvage surgery for patients with highly advanced or relapsed epithelial ovarian cancer (eoc) complicated by bowel obstruction and resulting in short bowel syndrome (sbs) constitutes a therapeutic dilemma. |
| PubMedID- 25552305 | Malignant bowel obstruction in patients with recurrent ovarian cancer. |
| PubMedID- 25889313 | Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer. |
Page: 1